A total of 349 newly diagnosed or recurrent EGFR mutation-positive advanced NSCLC patients who visited the hospital from July 1st, 2013, to December 31st, 2020, were enrolled (Fig. 1). This evidence concerns the gene EGFR and non-small cell lung carcinoma.